Advancing Connectivity and Interoperability in Trials of Rheumatic Diseases
IAG, Image Analysis Group is an imaging expert company that helps to accelerate novel drug development by using the right analytical tools and modern trial infrastructure. This includes bringing AI, Machine Learning and smart image analysis methods to ensure the speed and cost-effectiveness, while delivering true insights about your mechanism of action and patients’ response, in real-time.
ZiteLab bridges the gap between patients, healthcare providers and the IT systems that have grown into an indispensable part of the healthcare experience. This includes long term partnerships with University Hospitals and other private and public research driven institutions.
DYNAMIKA, IAG’s cloud-based platform, greatly improves efficiencies and data control for management of all imaging components within clinical trials by combining state-of-the-art infrastructure with built-in AI-driven algorithms to generate robust trial endpoints. Its cloud architecture allows the seamless merge of real time quality control, review and reporting of image data with most commonly used scoring systems.
SAMRI, ZiteLab’s platform has been developed in conjunction with rheumatology key opinion leaders and seamlessly integrates an intuitive interface for the scoring of the most complex of anatomies by radiologists, particularly in rheumatoid and psoriatic arthritis.
The partners will integrate SAMRIs optimized scoring tools with DYNAMIKA’s image management and viewing functionality to provide a comprehensive platform for global multi-centre clinical trials, testing therapies for rheumatic diseases.
This partnership will be a key driver for efficiency within clinical trials as well as building the foundation to understand better the analysis as performed by users for future improvements.
“This partnership will help bio-pharma companies developing novel therapeutics to tackle chronic diseases and diseases of aging. This modern trial infrastructure allows to deploy a wide range of novel imaging and scoring criteria in the trials. Thus, helping to accelerate clinical development of novel therapeutic agents and drive accuracy and speed of the patient response assessments“, commented Jamshid Dehmeshki, Chief Technology Officer at IAG.
“Ultimately, having the cloud infrastructure and novel methods for treatment efficacy assessment in once place will lead to much more targeted R&D, reduced costs and timelines of clinical development, ” added Dr. Olga Kubassova, CEO of IAG. “Such collaboration can truly be part of key drivers to operational efficiency. Our imaging experts’ and clinical collaborators’ data will be centralised and simultaneously available, therefore improving overall study transparency. We have the potential to provide a more comprehensive outlook on the factors influencing treatment efficacy evaluation, which in turn guarantees effective delivery of safe and efficacious treatments to patients.” added Romiesa Hagoug, Senior Clinical Project Manager at IAG
“We are proud of our work at the forefront of this exciting research and support the development of novel therapeutic agents,” Niels Steen Krogh, CEO of ZiteLab
IAG, Image Analysis Group is a strategic partner to bio-pharmaceutical companies developing new treatments to improve patients’ lives. We fuse decades of therapeutic insights, risk-sharing business model and agile culture to accelerate novel drug development. IAG broadly leverages its core imaging expertise, proprietary technology platform DYNAMIKA and capabilities to support an objective early go no/ go decision and drive excellence for tomorrow’s innovative therapeutic agents with speed.
IAG’s cloud platform for robust imaging data management in multi-centre trial setting and central review. One comprehensive software system to control trial progress, conduct central reads and use built-in AI for earlier read-outs and decision support. DYNAMIKA has powered over 100 global clinical studies, from ph I-IV linking more than 2000 sites, processing complex imaging data from thousands of patients. t can handle all types of imaging data, including MRI, CT, PET, SPECT and allows analysing it with state of the art or modern AI driven algorithms to generate trial endpoints.
About ZiteLab ApS:
ZiteLab bridges the gap between patients, healthcare providers and the IT systems that have grown into an indispensable part of the healthcare experience. Diversity, multiculturalism, alongside the interdisciplinary expertise makes the strength of ZiteLab and their partners who have developed clinical trial and disease registry solutions that are in use on local, regional, national and international levels in several languages. ZiteLab is engaged in international research collaborations with focus on AI backed personalised treatment and screening. and new diagnostic classifications. All IT systems are based on the same IT-platform combining python, R and webtechnologies.
For more information please reach out to <email@example.com>